O’Melveny Represents Keymed Biosciences in US$108 Million Top-up Placement
June 19, 2025
FOR IMMEDIATE RELEASE
HONG KONG—June 19, 2025— O’Melveny represented Keymed Biosciences (2162.HK) in its top-up placing transaction, involving a placing of 21,600,000 shares at HK$45.48 per share by its substantial shareholders and issuance of 19,000,000 new shares by Keymed Biosciences at the same placing price. The top-up placement was announced on June 11, 2025 and completed on June 19, 2025. The net proceeds received by Keymed Biosceinese is approximately US$108 million (approximately HK$854 million).
The transaction is an important advancement for Keymed Biosciences in its research and development efforts, as well as market expansion. The company intends to use the proceeds to accelerate the R&D and commercialization of several product lines and for working capital purposes.
Keymed Biosciences is a biotechnology company that focuses on developing treatments for autoimmune and cancer-related conditions in the PRC. Morgan Stanley acted as the sole overall coordinator, sole global coordinator and lead bookrunner. Goldman Sachs and Huatai Financial acted as the joint bookrunners.
The O’Melveny team was led by partners Ke Geng and Ke Zhu. The core team members included counsel Edward Poon and trainee solicitor Bianca Cheng.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com; learn more in our firm at-a-glance; and find us on LinkedIn, X, Facebook, Instagram, and YouTube.
Contact:
Brandon Jacobsen
O’Melveny & Myers LLP
+1 213 430 8024
bjacobsen@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com
# # #